Health care stocks were advancing premarket Friday, with The Health Care Select Sector SPDR Fund (XLV) up 0.3% and the iShares Biotechnology ETF (IBB) 0.4% higher.
Halozyme Therapeutics (HALO) shares were up over 11% after the company said it has withdrawn its proposal to acquire Evotec (EVO) for 11 euro ($11.47) per share in cash. Evotec shares were down past 20% pre-bell.
Eyenovia (EYEN) shares were over 9% higher after the company said Avenue Capital Management has agreed to support a potential restructuring of Eyenovia's loan and security agreement, and defer principal and interest payments on its outstanding debt until the end of February 2025.
Amneal Pharmaceuticals (AMRX) shares advanced by over 4% after the company said US regulators have approved its exenatide formulation as an adjunct treatment to help control glucose levels in the bloodstream of adults with type 2 diabetes mellitus.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。